CREATE Medicines is a biotech company developing in vivo CAR therapies using mRNA-LNP immune cell programming technology.
CREATE Medicines has raised $122.0M in total funding. The most recent round was Series B. The last funding was announced in May 2026.
CREATE Medicines's investors include ARCH Venture Partners, 8VC, Hatteras Venture Partners, Newpath Management, Alexandria Venture Investments.
CREATE Medicines is headquartered in Cambridge, United States.
CREATE Medicines is a biotech company developing in vivo CAR therapies using mRNA-LNP immune cell programming technology.
CREATE Medicines is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CREATE Medicines — Funding & Investors." VCBacked, May 14, 2026, https://www.vcbacked.co/company/create-medicines. Accessed October 30, 2026.
VCBacked. (2026). CREATE Medicines — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/create-medicines
{{cite web |title=CREATE Medicines — Funding & Investors |url=https://www.vcbacked.co/company/create-medicines |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated